Traders Watching Regeneron (REGN) Following Amgen (AMGN) AMG 145 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $414.55 -0.72%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: +2.5%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: +2.5%
Join SI Premium – FREE
Amgen (Nasdaq: AMGN) shares are ticking higher Monday morning following strong data from a Phase 1b clinical study of AMG 145. Shares are up about 1.7 percent ahead of the bell.
Earlier, Amgen reported that "The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001)."
Traders are keeping their sights on Regeneron (Nasdaq: REGN), Dendreon (Nasdaq: DNDN), Affymax (Nasdaq: AFFY), and BioGen (Nasdaq: BIIB).
Earlier, Amgen reported that "The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001)."
Traders are keeping their sights on Regeneron (Nasdaq: REGN), Dendreon (Nasdaq: DNDN), Affymax (Nasdaq: AFFY), and BioGen (Nasdaq: BIIB).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial
- Zuckerberg: Meta has reached AI ‘frontier,’ rejects calls for slowdown
- U.S. Pacific Command: Democratic People’s Republic of Korea launched two ballistic missiles on October 12
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
